Skip to content
Screener

Deferred Revenue at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.93B+2.2%
Labcorp Holdings logo
Labcorp HoldingsLH
$387.8M-2.6%
IQVIA logo
IQVIAIQV
$2.28B+7.4%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$502.7M+31.7%
NeoGenomics logo
NeoGenomicsNEO
$194K-82.1%
Simulations Plus logo
Simulations PlusSLP
$5.28M+21.5%

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.41B+35.7%
Enterprise value$16.05B+31.6%
P/E33.4×+4.5×
P/S5.9×+0.5×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
(Amounts in thousands, except share amounts)As of / June 30,2026As of / December 31,2025
Current liabilities:
Accounts payable (includes $0.1 million and $0.3 million with related parties at June 30, 2026 and December 31, 2025, respectively)$37,527$28,142
Accrued expenses451,076408,382
Advanced billings (includes $13.1 million and $12.3 million with related parties at June 30, 2026 and December 31, 2025, respectively)904,722854,390
Other current liabilities42,10452,834
Total current liabilities1,435,4291,343,748
Operating lease liabilities120,100113,643
Deferred income tax liability8,2071,355

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s deferred revenue?
Medpace Holdings, Inc. (MEDP) reported deferred revenue of $904.72M in Q2 2026.
How has Medpace Holdings, Inc.'s deferred revenue changed year-over-year?
Medpace Holdings, Inc.'s deferred revenue increased by 11.9% year-over-year, from $808.78M to $904.72M.
What is the long-term trend for Medpace Holdings, Inc.'s deferred revenue?
Over 5 years (2020 to 2025), Medpace Holdings, Inc.'s deferred revenue has grown at a 27.3% compound annual growth rate (CAGR), from $255.66M to $854.39M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Ask your AI about Medpace Holdings, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude